Bristol Myers Squibb & Co (NYSE: BMY) released topline data from Phase 3 CheckMate -8HW trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to the investigator’s choice of chemotherapy as a first-line treatment for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer.
The study met the dual primary endpoint of progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) at a pre-specified interim analysis.
The dual immunotherapy combination of Opdivo plus Yervoy demonstrated a ...